Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466713 · ClinicalTrials.gov registry record · NA
Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
NCT00466713: Clinical Trial NA study, sponsored by Stanford University.
NCT00466713 is a NA study that was terminated before completion, run by Stanford University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00466713, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
Study Summary
This study will investigate the effects of rosiglitazone, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. The primary purpose of the study is to determine whether treatment with an insulin-sensitizing medication will improve the heart's ability to metabolize glucose (sugar).
Interventions
- DRUG Rosiglitazone therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-03 |
| Est. Completion | 2007-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00466713
The ClinicalTrials.gov registry entry for NCT00466713 describes a study currently listed as terminated, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rosiglitazone therapy is the first listed.
NCT00466713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00466713 about?
NCT00466713 is a clinical study titled "Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy". This study will investigate the effects of rosiglitazone, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. The primary purpose of the study is to determine whether treatment with an insulin...
What is the current status of trial NCT00466713?
This trial is currently terminated. It is a NA study. The study started on 2007-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00466713?
The interventions under investigation include: Rosiglitazone therapy (DRUG).
Who is sponsoring clinical trial NCT00466713?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.